Successful Remission of Recurrent Anaphylaxis after Omalizumab Administration in a Patient with Systemic Mastocytosis
- Author:
Hongran MOON
1
;
Hee Joon JANG
;
Choon Geun LEE
;
Young Chan KIM
;
Shin Hye YOO
;
Dong Soon LEE
;
Hye Ryun KANG
Author Information
- Publication Type:Case Report
- Keywords: Mastocytosis; Systemic; Anaphylaxis; Omalizumab
- MeSH: Anaphylaxis; Bone Marrow; Humans; Ketotifen; Leukotriene Antagonists; Male; Mast Cells; Mastocytosis; Mastocytosis, Cutaneous; Mastocytosis, Systemic; Middle Aged; Omalizumab; Receptors, Histamine; Recurrence; Tryptases; Urticaria Pigmentosa
- From:Korean Journal of Medicine 2018;93(1):68-73
- CountryRepublic of Korea
- Language:Korean
- Abstract: Mastocytosis is a disorder characterized by abnormal mast cell proliferation and accumulation in one or more tissues. It presents in two major variants: cutaneous mastocytosis and systemic mastocytosis. Because the symptoms are related to mast cells, histamine receptor antagonists and leukotriene receptor antagonists are recommended as therapeutic options. Here, we report a 54-year-old male patient with a history of urticaria pigmentosa who presented with recurrent anaphylaxis. His serum tryptase level was 31.7 ng/mL and mast cell infiltration was observed in his bone marrow. He had frequent attacks of anaphylaxis despite treatment with ketotifen, levocetirizine, and montelukast. Symptoms related to systemic mastocytosis were controlled and the patient exhibited no recurrence of anaphylaxis following the introduction of monthly omalizumab injection. Omalizumab can be considered as a treatment option in patients with systemic mastocytosis unresponsive to conventional oral medications.
